6827.TWO MegaPro Biomedical Co., Ltd
- Market cap
- TWD 1.06B
- P/E
- -
- P/B
- 5.03x
- ROE
- -45.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6827.TWO undervalued?
Graham numberThe Graham number of MegaPro Biomedical Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MegaPro Biomedical Co., Ltd fundamental analysis
No fundamental analysis for MegaPro Biomedical Co., Ltd yet.
MegaPro Biomedical Co., Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 20…
Full company profileMegaPro Biomedical Co., Ltd financial statements
MegaPro Biomedical Co., Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 7.43M | 0.00 | 0.00 | 18.0K | 14.0K | 0.00 |
| Gross Profit | - | 7.43M | -7.54M | -13.6M | -16.6M | -17.2M | - |
| Operating Income | -178M | -149M | -101M | -122M | -140M | -180M | -120M |
| EBITDA | -178M | -143M | -81.6M | -97.4M | -110M | -146M | -104M |
| Net Income | -175M | -149M | -89.2M | -112M | -128M | -164M | -119M |
| EPS | -3.58 | -2.90 | -1.65 | -2.02 | -2.46 | -2.68 | -1.50 |
| Balance Sheet | |||||||
| Total Assets | - | 265M | 433M | 343M | 295M | 224M | 279M |
| Total Liabilities | - | 18.8M | 26.8M | 28.3M | 25.5M | 20.0M | 16.3M |
| Shareholders' Equity | - | 246M | 406M | 314M | 269M | 204M | 263M |
| Cash & Short-term Investments | - | 95.2M | 352M | 144M | 188M | 87.7M | 112M |
| Total Debt | - | - | 16.0M | 10.9M | 8.32M | 5.65M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -171M | -156M | -85.0M | -82.8M | -99.7M | -144M | -116M |
| Capital Expenditure | 963K | 7.52M | 17.9M | 13.5M | 4.39M | 1.17M | 893K |
| Free Cash Flow | -172M | -164M | -103M | -96.3M | -104M | -145M | -117M |
| Ratios | |||||||
| ROE | - | -60.4% | -22.0% | -35.5% | -47.4% | -80.3% | -45.3% |
| ROA | - | -56.1% | -20.6% | -32.6% | -43.3% | -73.1% | -42.7% |
| Net Profit Margin | - | -2,003.8% | - | - | -708,600.0% | -1,171,721.4% | - |
| Debt to Equity | - | - | 0.04x | 0.03x | 0.03x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MegaPro Biomedical Co., Ltd dividends
MegaPro Biomedical Co., Ltd has not paid dividends in the last 7 fiscal years.
Who owns MegaPro Biomedical Co., Ltd
Ownership data of MegaPro Biomedical Co., Ltd is not available yet.
MegaPro Biomedical Co., Ltd company profile
- Company name
- MegaPro Biomedical Co., Ltd
- Ticker
- 6827.TWO
- ISIN
- TW0006827009
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 66, Shengyi 5th Rd., Zhubei, Taiwan, 302
- Phone
- 886 3 591 0360
- Website
- megaprobio.com
About MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.
MegaPro Biomedical Co., Ltd management
1- Dr. Jassy WangChief Executive Officer